DoD Rare Cancers, Idea Development Award | HT942524RCRPIDA

Opportunity Information: Apply for HT942524RCRPIDA

The FY24 Department of Defense (DoD) Rare Cancers Research Program (RCRP) Idea Development Award is a grant opportunity designed to push forward fresh, early-stage research concepts that could open up new directions in rare cancer research. The program is looking for projects that are not yet fully mature but are far enough along to be supported by preliminary evidence, with the goal of generating influential data that can set up larger breakthroughs. In practice, this award is meant to help investigators turn a promising, well-reasoned idea into a more developed line of investigation that could ultimately contribute to reducing deaths and suffering from rare cancers.

A central requirement is that the proposed work is built around a clear, testable hypothesis supported by strong scientific rationale. Applicants must include preliminary data that make a convincing case the project is feasible, including a disease-specific rationale for why the approach should matter in the rare cancer context. Importantly, the preliminary data do not have to come directly from the exact rare cancer type or subtype being proposed; they can come from related systems, from collaborators, from the investigators laboratory (including unpublished findings), or even from outside the rare cancers field, as long as the application connects those data to the rare cancer question in a logical and scientifically defensible way.

The award places major emphasis on impact, not just scientific quality. The proposal needs to clearly explain how the results could lead to meaningful advances for rare cancers, such as enabling new biological insights, improving diagnostic pathways, identifying therapeutic vulnerabilities, or laying groundwork for future translational progress. Even a technically excellent project may be considered a poor fit if it does not make a strong, explicit case for high potential impact on rare cancers.

The funding opportunity also highlights specific areas of interest and broader DoD relevance. Innovative research using nuclear medicine and related technologies is encouraged, particularly when it supports earlier diagnosis, more effective treatment, and better outcomes for active-duty Service Members and their families. This includes work that could improve noninvasive diagnostic or targeted treatment capabilities and help drive precision imaging or advanced targeted therapies. In addition, because CDMRP participates in a congressionally mandated Metastatic Cancer Task Force, applicants are encouraged to align ideas with the Task Force recommendations on accelerating clinical and translational research for advanced and recurrent cancer, as long as the proposed work fits within the awards scope and the FY24 RCRP priorities.

There is also a strong encouragement for studies that address womens health considerations, especially conditions that affect women uniquely, disproportionately, or differently than men. Applicants are encouraged to incorporate sex as a biological variable when relevant and to connect anticipated findings to improvements in womens health outcomes or to advancing knowledge specific to womens health.

Methodological rigor and reproducibility are treated as core expectations. Projects should follow established best practices for study design and reporting, including principles such as randomization, blinding, sample-size estimation, and transparent data handling. The opportunity points to widely cited guidance on transparent reporting to strengthen the predictive value and translational potential of preclinical research, while noting that these principles also reflect long-standing clinical research standards.

From a teaming and collaboration standpoint, applications are open to all eligible applicants (listed as unrestricted), and the program strongly encourages proposals from military investigators as well as multidisciplinary partnerships spanning academia, industry, the military services, the Department of Veterans Affairs, and other federal agencies. If a project depends on access to special resources, datasets, or unique populations, the application must document that access at submission and describe how access will be maintained throughout the project period.

Finally, this mechanism does not allow clinical trials. The opportunity uses the federal regulatory definition of a clinical trial (45 CFR 46.102), meaning studies where human subjects are prospectively assigned to an intervention to evaluate effects on health-related outcomes are not permitted. However, studies involving humans that do not evaluate safety, effectiveness, or efficacy outcomes of an intervention may still be acceptable, depending on the design. Administrative details provided include the opportunity number HT942524RCRPIDA, administering agency USAMRAA (Department of the Army), CFDA 12.420, an original closing date of September 23, 2024, and an expected number of awards of 11 (the award ceiling is not specified in the provided text).

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Rare Cancers, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-04-19.
• Applicants must submit their applications by 2024-09-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 11 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524RCRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: